Oral Genome is a healthcare startup that has developed saliva tests to detect and prevent oral diseases. The company's technology utilizes computer vision paired with a tablet or smartphone as a reading device, along with test cards to assist in the early diagnosis and detection of dental diseases such as caries and periodontal disease.
The saliva testing kit analyzes specific biomarkers related to oral and systemic health, such as MMP-8, an early marker for periodontal disease, in 15 minutes. The tests provide personalized reports that help in risk stratification and targeted interventions for conditions like cavities, gum disease, and diabetes.
As of September 2024, the company's testing kits were available in the market and could be used at home or in clinical settings. The business model included one-time purchases and value-added online services.
Key customers and partnerships
Oral Genome mainly operates on a B2B2C model, partnering with dental practices, public health organizations, and insurance companies to offer its diagnostic tests. As of October 2024, the company was expanding into a D2C model, allowing individuals to purchase kits online for personal use.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.